LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- (), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City.
Presentation Details
Format: Virtual Corporate Presentation
Date: Monday, September 12, 2022
Time: Available for on-demand viewing at 7:00 a.m. EDT
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: . A replay will be archived for 90 days following the presentation date.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit , and follow us on , and .
CONTACTS
Investor Relations
Argot Partners (IR/Media)
212-600-1902
